Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Failure to Monitor and Document Anticoagulant Side Effects

Los Angeles, California Survey Completed on 05-09-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure adequate monitoring and documentation of potential side effects for a resident who was receiving Lovenox, an anticoagulant medication. The resident, who had a history of a displaced intertrochanteric fracture of the left femur, anemia, and hyperlipidemia, was prescribed Lovenox injections for DVT prophylaxis. Despite receiving the medication as ordered, there was no documentation in the electronic medical record to indicate that the resident was monitored for signs and symptoms of bleeding, a known risk associated with anticoagulant therapy. During interviews and record reviews, the Director of Nursing confirmed that staff are expected to monitor and document any side effects of Lovenox, including bleeding, in the electronic medical record. However, a review of the resident's Medication Administration Record and electronic medical record revealed no evidence that such monitoring occurred during the period the resident received Lovenox. The facility's policy on high-risk medications, including anticoagulants, requires staff to monitor for adverse consequences and document these observations, but this was not followed in this case.

An unhandled error has occurred. Reload 🗙